Abstract

Breast cancer is the most common cancer in women worldwide and 2nd common cancer after cervix in India. Presence of p53 gene alteration like loss of function p53 mutants correlate with poor prognosis and tend to be more frequent in high grade, large size, node positive, and in estrogen-progesterone receptor negative (ER-, PR-) tumors, suggesting that mutant p53 may become increasingly critical for breast cancer progression. To determine the frequency of expression of p53 immunostaining (IHC) in breast carcinomas and to correlate its relationship with tumor size, histological grade, lymph node status and with hormonal receptors status wherever possible. Sixty-fi ve breast carcinoma cases were studied for various clinicopathological parameters like tumor size, histological type, grade, axillary lymph node status, lympho vascular invasion, in situ component, Nipple areola complex, deep resected margin involvement, Nottingham Prognostic Index (NPIG) and subjected to p53 immunostaining. 37 out of 65 cases were studied for ER, PR, Human Epidermal Growth Factor Receptor 2 (HER2/ neu) antibodies. p53 expression was correlated with known prognostic factors. Furthermore, autopsy studies can be used as supplement to know the disease reservoir. p53 positivity was found in 72.3% of breast carcinomas with signifi cant association between p53 expression with histological grade (p-value = 0.013) and Nottingham Prognostic Index Groups (NPIG) (p-value = 0.011). No signifi cant correlation was seen between p53 expression and tumor size, lymph node status, hormonal receptor (ER, PR) status and HER2/neu expression. Our study revealed that the higher the tumor grade, the higher the p53 expression and its association with NPIG. Thus, p53 can be considered as a prognostic marker and useful for management.

• 1.   Walerych D, Napoli M, Collavin L and Sal GD. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012;33(11):1-11.
• 2.   Singh S et al. p53 gene. Mutation and immunohistochemical analysis in patients with invasive ductal Biotechnol 2013;9(4): 395-403.
• 3.   Khaliq T, Afghan S, Naqi A, Haider MR. p53 Mutations in Carcinoma Breast - a Clinicopathological Study. JPMA 2001;51:21-25.
• 4.   Abdollahi A, Sheikhbahaei S, Safinejad S and Jahanzad I. Correlation of ER, PR, HER- 2 and p53 Immunoreactions with ClinicoPathological Features in Breast Cancer. J Korean Med Sci 2013; 8(3):147-152.
• 5.   Taylor CR, Shi SR, Barr NJ, Wu N. Techniques of immunohistochemistry: principles, pitfalls, and standardization. Diagnostic immunohistochemistry. 2nd edition, Churchill Livingstone. Elsevier; 2006: 3-44.
• 6.   Pan Y, Yuan Y, Liu G, Wei Y (2017) P53 and Ki-67 as prognostic markers in triple- negative breast cancer patients. PLOS ONE 12(2): e0172324.
• 7.   Acroix M, Toillon RA, Leclercq G. p53 and breast cancer, an update. Endocr Relat Cancer. 2006;13(2):293-325.
• 8.   Lane DP. Cancer: p53, guardian of the genome. Nature. 1992;358(6381):1516.
• 9.   Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;70(4):523-6.
• 10.   Elledge R.M., Fuqua S.A.W., Clark G.M., Pujol P. and Allred D.C. The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res. Treat. 1993;27(1-2):95- 102.
• 11.   Ho GH, Calvano JE, Bisogna M, et al. In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology. Cancer 2000;89(11):2153-60.
• 12.   Done SJ, Eskandarian S, Bull S, Redston M, Andrulis IL. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. J Natl Cancer Inst 2001;93(9): 700- 704.
• 13.   Malamou-Mitsi V, Gogas H, Dafni U, et al. Evaluation of the prognostic and predictive value of p53 and bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant therapy. Ann Oncol 2006; 17 (10): 1504-11.
• 14.   Borresen-Dale AL. TP53 and breast cancer. p53 review article. Hum Mutat 2003; 21: 292-300.
• 15.   Deb P, Deshpande GU, Rai R., Correlationship of hormone receptor status, p53 mutation and c – erb B – 2 overexpression with nuclear grading in breast cancers. Med J Armed Forces India. 2000;56(4):305-308.
• 16.   Ryu JW, Lee MC, Jang WC. Detecting p53 gene mutation of breast cancer and defining differences between silver staining PCR-SSCP and immunohistochemical staining. J Korean Med Sci. 2000;15(1):73-77.
• 17.   Patnayak R, Jena A, Rukmangadha N, Chowhan A, Sambasivaiah K, Phaneendra B, et al. Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience. Indian J Med Paediatr Oncol. 2015;36(2):117-22.
• 18.   Sekar P, Bharti JN, Nigam JS, Sharma A, Soni PB. Evaluation of p53, HoxD10, and E-Cadherin Status in Breast Cancer and Correlation with Histological Grade and Other Prognostic Factors. Journal of Oncology. 2014;2014:1–4.
• 19.   Gupta K. Correlation of p53 Expression with clinicopathological characteristics of breast carcinoma. Annals of Pathology and Laboratory Medicine. 2016;03(03):162 -170.
• 20.   Al-Joudi FS, Iskandar ZA, Rusli J. The expression of p53 in invasive ductal carcinoma of the breast: a study in the North-East States of Malaysia. Med J Malaysia. 2008;63(2):96–99.
• 21.   Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic Factors in Breast Cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000 Jun;124:966–78.
• 22.   Michaelson JS, Silverstein M, Sgroi D, Cheongsiatmoy JA, Taghian A, Powell S et al. The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer. 2003 Nov 15;98(10):2133-43.
• 23.   Sheikhpour R, Ghassemi N, Yaghmaei P, Ardekani JM, Shiryazd M. Immunohistochemical Assessment of p53 Protein and its Correlation with Clinicopathological Characteristics in Breast Cancer Patients. Indian Journal of Science and Technology. 2014;7(4):472-9.
• 24.   Lebe BA, Canda TÜ, Tuna BU, Sagol O, Ozer E. The evaluation of p53 and Ki67 expressions in invasive micropapillary carcinoma of the breast and its relation with other prognostic parameters: Thirty two cases. Turk J Cancer. 2002; 32(2):48-56.
• 25.   Rakha EA, El-Sayed ME, Lee AHS, Elston CW, Grainge MJ, Hodi Z, et al. Prognostic significance of Nottingham Histologic Grade in invasive breast carcinoma. J Clin Oncol. 2008;26(19):3153- 58.
• 26.   Cass J, Varma S, Day A, Sangrar W, Rajput A, Raptis L et al. Automated Quantitative Analysis of p53, Cyclin D1, Ki67 and pERK Expression in Breast Carcinoma Does Not Differ from Expert Pathologist Scoring and Correlates with Clinico-Pathological Characteristics. Cancers. 2012;4(3):725742.
• 27.   Sirvent JJ, Salvado MT, Santafe M, Martinez S, Brunet J, Alvaro T, Palacios J. p53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (ki-67) and c-erbB-2. Immunohistochemical study of 153 cases. Histol Histopathol 1995; 10:531-9.
• 28.   Singh S, Rajput S, Mishra P, Mohan G, Kumar M, Singh R et al. P53 gene: Mutation and immunohistochemical analysis in patients with invasive ductal carcinoma of breast. American Journal of Biochemistry and Biotechnology. 2013;9(4):395-403.
• 29.   Soerjomataram I, Louwman MJ, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factor for long term survivors of breast cancer. Breast Cancer Res Treat 2008;107(3):309-30.
• 30.   Han J, Cao D, Molberg K, Sarode V, Rao R, Sutton L et al. Hormone Receptor Status Rather Than HER2 Status Is Significantly Associated With Increased Ki-67 and p53 Expression in Triple-Negative Breast Carcinomas, and High Expression of Ki-67 but Not p53 Is Significantly Associated with Axillary Nodal Metastasis in Triple-Negative and High-Grade Non–Triple Negative Breast Carcinomas. Am J of Clin Pathol. 2011;135(2):230-237.
• 31.   Ivkovic-Kapicl T, Panjkovic M, Nincic D, Knezevic-Usaj S. Factors correlating with lymph node metastases in patients with T1 ductal invasive breast cancer. Arch oncol. 2006;14(1-2):19-22.
• 32.   Kurshumliu F, Gashi-Luci L, Kadare S, Alimehmeti M, Gozalan U. Classification of patients with breast cancer according to Nottingham Prognostic Index highlights significant differences in immunohistochemical marker expression. World J Surg Oncol. 2014;12(1):243-7.
• 33.   Cengiz-Boduroglu E, Irkkan Ç, Bilir G. Is Nothingham Prognostic Index correlated with apoptosis and P53 expression in infiltrating ductal carcinoma of the breast?. Pathology & Oncology Research. 2003;9(2):100-103.
• 34.   Howell A, Harland R, Bramwell V, Swindell R, Barnes D, Redford J et al. Steroid-hormone receptors and survival after first relapse in breast cancer. The Lancet. 1984;323(8377):588-591.
• 35.   McGuire W, Horwitz K, Pearson O, Segaloff A. Current status of estrogen and progesterone receptors in breast cancer. Cancer. 1977;39(6):2934-2947.
• 36.   Pertschuk L, Eisenberg K, Carter A, Feldman J. Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies. Correlation with biochemistry and clinical endocrine response. Cancer. 1985;55(7):1513-1518.
• 37.   Alireza A, Sheikhbahaei S, Safinejad S, Jahanaz I. Correlation of ER, PR, HER - 2 and P53 Immunoreactions with Clinico - Pathological Features in Breast Cancer. Iranian Journal of Pathology. 2013;8(3):147-152.
• 38.   Mortenson ED, Fu YX. Adaptive Immune Responses and HER2/ neu-Positive Breast Cancer. Curr Pathobiol Rep. 2013 Mar 1;1(1):37-42.
• 39.   Shokouh T, Ezatollah A, Barand P. Interrelationships Between Ki67, HER2/ neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes. Medicine. 2015;94(32):e1359.
• 40.   Rashed MM, Ragab NM, Galal MK. The association of HER-2/neu overexpression in relation to p53 nuclear accumulation, hormonal recceptor status and common clinico-pathological prognostic parameters in a series of Egyptian women with invasive ductal carcinoma. European Journal of General Medicine. 2007;4(2): 73–79.

Data Sharing Statement

Funding